Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer

Lung Cancer

Volumn 66, Issue 3, 2009, Pages 350-354

  Isobe, Kazutoshi ^a   Kobayashi, Kunihiko ^b   Kosaihira, Seiji ^f   Kurimoto, Futoshi ^c   Sakai, Hiroshi ^c   Uchida, Yuka ^b   Nagai, Yoshiaki ^b   Yamaguchi, Takefumi ^b   Miyanaga, Akihiko ^d   Ando, Makoto ^d   Mori, Gaku ^d   Hino, Mitsunori ^e   Gemma, Akihiko ^f  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d Tsuboi Hospital   (Japan)

^e NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

ACNU; Lung neoplasms; Nimustine; Paclitaxel; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; NIMUSTINE; PACLITAXEL; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG SMALL CELL CANCER; LUNG TOXICITY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIMUSTINE; PACLITAXEL; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS;

EID: 70350621082     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.003     Document Type: Article

References (30)

1. Simon G.R., and Turrisi A. American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (2007) 324S-329S
2. Hansen H.H. Management of small-cell cancer of the lung. Lancet 339 (1992) 846-849
3. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
4. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006) 2038-2043
5. Hermes A., Bergman B., Bremnes R., Ek L., Fluge S., Sederholm C., et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 26 (2008) 4261-4267
6. Natale R.B., Lara P.N., Chansky K., Crowley J.J., Jett J.R., Carleton J.E., et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). Proc Am Soc Clin Oncol 26 (2008) 400s
7. Turrisi III A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999) 65-71
8. Sundstrøm S., Bremnes R.M., Kaasa S., Aasebø U., Hatlevoll R., Dahle R., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20 (2002) 4665-4672
9. Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 (1992) 1618-1624
10. Jassem J., Karnicka-Młodkowska H., van Pottelsberghe C., van Glabbeke M., Noseda M.A., Ardizzoni A., et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 29 (1993) 1720-1722
11. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15 (1997) 2090-2096
12. Von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999) 658-667
13. Kakolyris S., Mavroudis D., Tsavaris N., Souglakos J., Tsiafaki P., Kalbakis K., et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 12 (2001) 193-197
14. Masters G.A., Declerck L., Blanke C., Sandler A., DeVore R., Miller K., et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer. J Clin Oncol 21 (2003) 1550-1555
15. O'Brien M.E., Ciuleanu T.E., Tsekov H., Shparyk Y., Cuceviá B., Juhasz G., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (2006) 5441-5447
16. Onoda S., Masuda N., Seto T., Eguchi K., Takiguchi Y., Isobe H., et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24 (2006) 5448-5453
17. Eckardt J.R., von Pawel J., Pujol J.L., Papai Z., Quoix E., Ardizzoni A., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25 (2007) 2086-2092
18. Park S.H., Cho E.K., Kim Y., Kyung S.Y., An C.H., Lee S.P., et al. Salvage treatment with topotecan in patients with irintopotecan-refractory small cell lung cancer. Cancer Chemother Pharmacol 62 (2008) 1009-1014
19. Planting A.S., Splinter T.A., Ardizzoni A., Estapé J., Giaccone G., Kirkpatrick A., et al. Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. Cancer Chemother Pharmacol 29 (1992) 409-411
20. Saijo N., and Niitani H. Experimental and clinical effect of ACNU in Japan with emphasis on small-cell carcinoma of the lung. Cancer Chemother Pharmacol 4 (1980) 165-171
21. Wakui A. Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas. Gan To Kagaku Ryoho 9 (1982) 1327-1338
22. Ettinger D.S., Finkelstein D.M., Sarma R.P., and Johnson D.H. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13 (1995) 1430-1435
23. Kirschling R.J., Grill J.P., Marks R.S., Kugler J.W., Gerstner J.B., Kuross S.A., et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 22 (1999) 517-522
24. Smit E.F., Fokkema E., Biesma B., Groen H.J., Snoek W., and Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77 (1998) 347-351
25. Yamamoto N., Tsurutani J., Yoshimura N., Asai G., Moriyama A., Nakagawa K., et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 26 (2006) 777-781
26. Fujiwara K., Yamauchi H., Suzuki S., Ishikawa H., Tanaka Y., Fujiwara M., et al. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother Pharmacol 47 (2001) 22-26
27. Ishikawa H., Fujiwara K., Suzuki S., Tanaka Y., and Kohno I. Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients. Int J Clin Oncol 7 (2002) 330-333
28. Kobayashi K., Komagata H., Sakai H., and Yoneda S. Nimustine hydrochloride (ACNU) plus paclitaxel (Taxol) for refractory or relapsed lung cancer. Proc Am Soc Clin Oncol 21 (2002) 222b
29. Yana T., Negoro S., Takada M., Yokota S., Takada Y., Sugiura T., et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 25 (2007) 253-258
30. Ando M., Kobayashi K., Yoshimura A., Kurimoto F., Seike M., Nara M., et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44 (2004) 121-127